Roswell Park Comprehensive Cancer Center

Roswell Park-led study reveals benefits of combining adoptive cell therapy with immune checkpoint inhibitors in ovarian cancer.

A study led by Roswell Park researchers zeroes in on why some newly diagnosed glioblastoma patients survive longer than others after standard treatment plus SurVaxM.

Roswell Park Comprehensive Cancer Center endorsed a statement urging health care systems and professionals to choose HPV vaccination for cancer prevention.

Five new faculty members join network; three at St. Joseph’s Health in Syracuse as it launches new services.

Patients with lung cancer who take GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes management—fare better than those who don’t.

Findings reveal that cancer genomics similar to other populations, but with some distinctive features.

Health services company recognizes joint care offered through collaboration with Roswell Park Oishei Children’s Hospital.

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies.

A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys

Doctors join cancer center with expertise in surgical and medical oncology, pathology, dermatology, anesthesia.

Research centers across New York State are collaborating to develop cell therapies for cancer to expand progress in the emerging field of cell therapy.

Renier Brentjens, MD, PhD, invited to address Damon Runyon Foundation, New York Academy of Sciences

Roswell Park Comprehensive Cancer Center has been added to Newsweek’s list of America’s Best Cancer Hospitals for 2025.

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.

Faculty from Roswell Park Comprehensive Cancer Center are among the experts invited to share their research findings at the 2025 ASCO Annual Meeting.

Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues at the 2025 AACR Annual Meeting.

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 robot-assisted minimally invasive esophagectomies from 2020-2024.

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

Roswell Park-led study takes a significant step toward relief without opioid.

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.